Assembly Biosciences Inc
Assembly Biosciences Inc (ASMB) Historical Volatility
ASMB's 30 day historical volatility is 64.65%, in the 77th percentile of readings over the past year. This is a high percentile, meaning Assembly Biosciences Inc shares have swung far more than usual. ASMB's 30 day implied volatility sits at 127.56%, with an IV Rank of 90.08%, leaving IV 62.91 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 17, 2026.
Read more
Tracking ASMB historical volatility helps you see how much Assembly Biosciences Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ASMB's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ASMB 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ASMB's 30 day historical volatility, or ASMB HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ASMB's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 17, 2026
As of Nov 17, 2026
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →